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Specific Thiazolidinediones Inhibit Ovarian Cancer Cell
Line Proliferation and Cause Cell Cycle Arrest in a PPARc
Independent Manner
Linah Al-Alem1,2, R. Chase Southard1, Michael W. Kilgore1, Thomas E. Curry2*
1 Department of Molecular and Biomedical Pharmacology, University of Kentucky College of Medicine, Lexington, Kentucky, United States of America, 2 Department of
Obstetrics and Gynecology, University of Kentucky College of Medicine, Lexington, Kentucky, United States of America

Abstract
Background: Peroxisome Proliferator Activated Receptor gamma (PPARc) agonists, such as the thiazolinediones (TZDs),
have been studied for their potential use as cancer therapeutic agents. We investigated the effect of four TZDs—
Rosiglitazone (Rosi), Ciglitazone (CGZ), Troglitazone (TGZ), and Pioglitazone (Pio)—on ovarian cancer cell proliferation,
PPARc expression and PPAR luciferase reporter activity. We explored whether TZDs act in a PPARc dependent or
independent manner by utilizing molecular approaches to inhibit or overexpress PPARc activity.
Principal Findings: Treatment with CGZ or TGZ for 24 hours decreased proliferation in three ovarian cancer cell lines,
Ovcar3, CaOv3, and Skov3, whereas Rosi and Pio had no effect. This decrease in Ovcar3 cell proliferation was due to a higher
fraction of cells in the G0/G1 stage of the cell cycle. CGZ and TGZ treatment increased apoptosis after 4 hours of treatment
but not after 8 or 12 hours. Treatment with TGZ or CGZ increased PPARc mRNA expression in Ovcar3 cells; however, protein
levels were unchanged. Surprisingly, luciferase promoter assays revealed that none of the TZDs increased PPARc activity.
Overexpression of wild type PPARc increased reporter activity. This was further augmented by TGZ, Rosi, and Pio indicating
that these cells have the endogenous capacity to mediate PPARc transactivation. To determine whether PPARc mediates
the TZD-induced decrease in proliferation, cells were treated with CGZ or TGZ in the absence or presence of a dominant
negative (DN) or wild type overexpression PPARc construct. Neither vector changed the TZD-mediated cell proliferation
suggesting this effect of TZDs on ovarian cancer cells may be PPARc independent.
Conclusions: CGZ and TGZ cause a decrease in ovarian cancer cell proliferation that is PPARc independent. This concept is
supported by the finding that a DN or overexpression of the wild type PPARc did not affect the changes in cell proliferation
and cell cycle.
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One of the therapeutic targets under investigation for ovarian
cancer is nuclear receptors. Drugs that activate or inhibit nuclear
receptors have been used to treat many diseases. Indeed, about
13% of the drugs currently on the market target nuclear receptors
[6]. PPARc is a highly conserved nuclear receptor [7] expressed
throughout the body [8] and is over expressed in many cancers,
including ovarian and breast cancer, making it a potentially
important player in the development of cancer.
Endogenous PPARc ligands are still unknown, but well characterized candidates include polyunsaturated fatty acids, Prostaglandin J2 (PGJ2) and arachidonic acid [9]. Synthetic PPARc ligands
include the thiazolidinediones (TZDs), which consist of Rosiglitazone (AvandiaH), Troglitazone (RezulinH), Pioglitazone (Glustin H/
ActosH), and Ciglitazone, all of which have been developed and/or
used to treat type II diabetes [10,11,12]. The use of TZDs as a
therapeutic approach in cancer has been investigated but results
have been controversial [13,14,15]. In this study we utilized
molecular, physiological and pharmacological approaches to

Introduction
Ovarian cancer is the fifth leading cause of cancer death in
women. Of the three main types of ovarian cancer (epithelial,
germ cell, and sex cord stromal cancers), epithelial ovarian cancer
accounts for about 90% of all cases, and is the first cause of death
from gynecological malignancies [1,2]. Despite intense research on
ovarian cancer with new targets being constantly investigated,
treatment targets remain sparse. One of the challenges in ovarian
cancer research is the absence of an experimental animal model
that recapitulates the human disease that can be experimentally
manipulated [1,3]. Thus, ovarian cancer cell lines have been
employed to understand the fundamental processes involved in
cancer cell growth, differentiation, and proliferation. The present
study utilized three ovarian cancer cells, Ovcar3, CaOv3 and
Skvo3, which are derived from human epithelial ovarian cancer
[4,5] to further explore therapeutic modalities in cancer cell
growth and proliferation.
PLoS ONE | www.plosone.org
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investigate the effect of the four different TZDs on ovarian cancer
cells and determine whether these effects are PPARc dependent or
independent.

Results
Ovcar3, CaOv3 and Skov3 ovarian cancer cell lines
express PPARc
In order to determine whether ovarian cancer cells express
PPARc, real time PCR and western blot analysis was performed.
There was differential PPARc expression in the three different cell
lines both at the mRNA and protein levels. While PPARc mRNA
expression was highest in Skov3 cells (Figure 1A), Skov3 cells had the
lowest PPARc protein levels (Figure 1B). In contrast, Ovcar3 had
low levels of PPARc mRNA expression but abundant expression of
PPARc protein (Figures 1A and 1B respectively). PPARc activity in
the three cell lines was examined using cells transfected with a
3XPPRE-Luc-Renilla construct and compared to cells transfected
with luciferase and Renilla constructs lacking the PPRE. Ovcar 3 cells
exhibited approximately 2 fold more endogenous PPRE activity
compared to CaOv3 cells, while Skov3 cells showed 50% more
PPRE activity compared to Ovcar3 cells (Figure 1C).

Retinoic Acid Receptor (RXR) is not a limiting factor in
PPARc activity
PPARc binds to its heterodimeric partner RXR before binding
to DNA [16]. RXR is known to be constitutively expressed in cells
and has been shown to heterodimerize with other receptors
besides PPARc, such as the vitamin D receptor [17]. For RXR to
be activated, its ligand 9-cis-retinoic acid (9-Cis-RA) needs to be
present. In order to insure that activated RXR is not a limiting
factor in our experiments, cells were treated with 9-Cis-RA. In
these experiments, cells were transfected with different PPARc
constructs including D467 which is a dominant negative (DN) form
of PPARc [18,19] as well as an over expression form of wild type
PPARc (OE) which is used to increase PPARc expression. A DN
form of PPARc was used throughout these studies based upon
initial experiments that revealed that DN transfection decreased
the PPRE activity 40% below levels in cells transfected with
ShRNA PPARc (data not shown). In order to insure that PPARc
was overexpressed whether in the DN or OE form compared to
control cells (i.e. cells transfected with PGL3), PPARc protein
expression was measured using western blot analysis. As expected
there was a marked induction of both the DN and OE form of
PPARc (Figure 2A insert). After transfection with the control, DN
or OE vector, cells were subsequently treated with vehicle control
or 1 mM of 9-Cis-RA for 24 hours in the dark. We observed that
the presence of 9-Cis-RA did not affect the activity of the PPARc
reporter assay in Ovcar 3 cells, indicating that activated RXR is
not a limiting factor in this cell line (Figure 2A). The addition of 9Cis-RA to CaOv3 cells did not change PPRE activity until PPARc
was overexpressed (Figure 2B) suggesting that activated RXR is
not rate limiting until PPARc is highly abundant in this cell line.
Surprisingly, in Skov3 cells, 9-Cis-RA increased the PPARc
reporter activity assay in control cells (PGL3) but had no effect
when PPARc was over expressed compared to control (Figure 2C).

Figure 1. Expression of PPARc in three ovarian cancer cell lines
(Ovcar3, CaOv3, Skov3). (A) mRNA expression (B) Protein expression
and (C) PPRE luciferase activity. Data was normalized to levels of PPARc
expression and activity in Ovcar3 cells. Results are the means 6 SEM for
at least 3 measurements from three individual experiments. Bars that do
not share a letter designation are significantly different (p,0.05). Cells
transfected with Luc and Renilla constructs lacking PPRE (PPRE 2) were
significantly lower than the same cell line transfected with PPRELuciferase-Renilla constructs (PPRE +) by Welch’s t-test (p,0.05).
doi:10.1371/journal.pone.0016179.g001

Administration of the four TZDs resulted in differences in cell
proliferation. Treatment with CGZ decreased proliferation 80%,
TGZ caused a 65% decrease, while Rosi and Pio had no effect on
proliferation (Figure 3A–D Black bars). In an effort to understand
whether the decrease in proliferation following TZD treatment is
common across other ovarian cancer cells, TZD treatment of
CaOv3 and Skov3 was explored. A similar decrease in proliferation
was seen in these cell lines when treated with CGZ and TGZ at

CGZ and TGZ cause a decrease in cell proliferation
To define the effects of PPARc ligands on cell proliferation, MTS
assays were performed. Ovcar3 cells were treated with concentrations of 0, 0.1, 1 or 10 mM of Rosi, CGZ, TGZ or Pio for 24 hours.
The maximum TZD concentration used was 10 mM since PPARc
specific actions are reported with TZDs at concentrations #10 mM
[20] and higher concentrations are known to induce cell death [21].
PLoS ONE | www.plosone.org
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Figure 2. Effect of 9-cis-Retinoic Acid (9-Cis-RA) treatment on Ovcar3, CaOv3 and Skov3 PPRE luciferase activity. Cells were double
transfected with a PPRE construct and one of the following: Empty vector (PGL3), DN form of PPARc (DN) or wildtype form of PPARc (OE). After the
double transfections, cells were treated for 24 hours with vehicle control (DMSO) or 1 mM of 9-Cis-RA in the dark. PPRE luciferase activity is illustrated
for (A) Ovcar3, (B) CaOv3, and (C) Skov3. Controls represent cells that were transfected with the empty vector and treated with vehicle control,
shown as the first bar in each panel. Results for the PPRE luciferase assay are the means 6 SEM for at least 9 measurements. Bars that do not share a
letter designation are significantly different (p,0.05). Insert Panel A: Western blot of PPARc protein in Ovcar3 cells double transfected with a PPRE
construct and either empty vector, DN or OE PPARc constructs and treated with vehicle control for 24 hours.
doi:10.1371/journal.pone.0016179.g002

10 mM. CaOv3 cells show an 80% and 30% decrease in cell
proliferation when treated with CGZ and TGZ, respectively
(Figure 3A–B). Skov3 cells show a 45% and 35% decrease when
treated with 10 mM CGZ and TGZ, respectively (Figure 3A–B).
Similar to Ovcar3 cells, CaOv3 and Skov3 cells treated with Rosi or
Pio did not exhibit a change in proliferation (Figure 3C–D).

study of ovarian cancer, facilitating comparison with previous
studies. In an attempt to better understand the mechanism
mediating the decrease in cell proliferation, we examined whether
apoptosis contributes to this decrease. We observed a decrease in
cell proliferation after 24 hours of treatment (Figures 3 and 4). If
this decrease is due to apoptosis, then this cell death should have
occurred at an earlier time point. Hence, we examined the effect of
TZDs on Ovcar3 cells and determined whether cells were either
viable or undergoing apoptosis and were dead at 4, 8 or 12 hours
after treatment using FACS analysis. There was a slight increase in
apoptotic and dead cells after 4 hours of treatment with CGZ and
TGZ (Figure 6A). However, this increase was not detected in
samples treated for 8 or 12 hours (Figure 6B and 6C). Trypan blue
experiments to confirm live versus dead cells showed similar results
(data not shown).

CGZ and TGZ decrease BrdU DNA incorporation
The MTS assay measures mitochondrial activity in cells, which
is indicative of their viability [22] and considered an indirect
assessment of cell proliferation. However, there is a report that the
TZDs can interfere with the MTS assay [23]. Therefore, we also
measured the rate of DNA replication in Ovcar3 cells using BrdU
incorporation as another index of cell proliferation. Ovcar3 cells
were treated with 0, 0.1, 1 or 10 mM of Rosi, CGZ, TGZ or Pio
for 24 hours. BrdU assays show similar results as those of the MTS
assay. There was approximately a 70% decrease in proliferation in
cells treated with 10 mM of CGZ or TGZ, and no effect of Rosi or
Pio on cell proliferation (Figure 4A–D).

CGZ and TGZ cause cell cycle arrest
In an effort to clarify the reason underlying the decrease in
proliferation, the effects of TZDs on cell cycle progression were
also assessed. A significant increase in cells in the G0/G1 phase was
seen following treatment with TGZ and CGZ (Figure 7A). CGZ
administration resulted in a significant decrease in G2/M phase of
the cell cycle (Figure 7B), while no changes in the S phase were
seen in cells treated with CGZ or TGZ (Figure 7C). Cells treated
with Rosi or Pio did not show any change in cell cycle distribution
compared to control (data not shown).

PPARc mRNA expression is enhanced by TZD treatment
of ovarian cancer cells
To evaluate the association of these ligands with regulation of
PPARc, we examined the effect of TZDs on expression of PPARc
in Ovcar3 cells. Cells were treated with or without 10 mM of
TZDs and PPARc mRNA and protein levels were analyzed
24 hours later. PPAR(expression was increased in Ovcar3 cells
treated with CGZ (6.9 fold) and TGZ (18.1 fold) (Figure 5A).
Surprisingly, there was an increase in PPAR(protein following
Rosi but not CGZ or TGZ treatment (Figure 5B). In an effort to
explain this discrepancy between mRNA and protein expression,
we investigated a time course of PPAR(mRNA and protein
expression. Cells were treated with the different TZDs for 4, 8, 12
or 24 hours and both real time PCR and Western blot analysis
were performed. We did not observe a correlation between the
expression patterns for PPAR(mRNA and protein across time
which indicates that there are potentially other mechanisms
affecting the levels of PPAR(protein in these cells. One possibility is
that the TZDs increase the turnover and degradation of
PPAR(protein as seen in other systems [24,25].
Since CGZ and TGZ caused a decrease in cell proliferation in
CaOv3 and Skov3 cells, we measured the mRNA expression of
PPARc in these cells. In CaOv3 cells, the mRNA expression of
PPARc after CGZ and TGZ treatment was 3.6 and 4.4 fold above
the vehicle control respectively although these changes did not reach
significance. Skov3 cells showed no changes in PPARc expression
after treatment with the TZDs (data not shown). Collectively, our
data indicates that PPAR(mRNA is present and is regulated by
TZDs in ovarian cancer cells albeit to different degrees depending
upon the cell type and the ligand used to activate PPARg.

Effects of TZDs on PPRE luciferase activity
To clarify whether the antiproliferative and cell cycle arrest
effects seen with select TZDs are a direct effect of PPARc
transactivation, we transiently transfected cells with a 3XPPREmTK-pGL3-reporter plasmid. Two additional constructs were
cotransfected, namely, a DN form of PPARc and an overexpression (OE) of a wildtype PPARc construct. Cells were then treated
for 24 hours with 10 mM of Rosi, CGZ, TGZ, or Pio. None of the
TZD treatments alone increased PPRE activity (Figure 8).
However, cells transfected with DN showed an approximate
40% decrease in PPRE mediated activity in both untreated and
TZD treated cells. Furthermore, increasing the expression of the
wild type PPARc showed an increase in luciferase activity when
cells were treated with any of the four different TZDs compared to
cells that were only treated with TZDs (Figure 8A–8D).

Analysis of TZD mediated PPARc dependent and
independent actions
In order to determine whether the effects of TZDs are PPARc
dependent, cells were treated with 10 mM TZDs in the absence or
presence of PPARc antagonists (GW9662, T007). The MTS assay
was performed in order to determine whether the presence of
antagonists could reverse the effects of TZDs on ovarian cancer
cell proliferation. Results showed that there was a partial ‘rescue’
when cells were treated with the GW9662 (Figure 9A) or the T007
(Figure 9B) compounds in combination with CGZ or TGZ.
However, the pattern of action was inconsistent between the two
antagonists and even with the same antagonist in the presence of

CGZ and TGZ do not induce apoptosis
In this and subsequent experiments we examined only Ovcar3
cells as these cells showed the most notable effects when treated
with TZDs. Furthermore, these cells are commonly used in the
PLoS ONE | www.plosone.org
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Figure 3. Effect of TZD treatment on Ovcar3, CaOv3 and Skov3 cell proliferation. Ovarian cancer cells were serum starved for 24 hours and
treated for an additional 24 hours with vehicle control (DMSO) or 0.1, 1.0 or 10 mM of CGZ (A), TGZ (B), Rosi (C), or Pio (D). Cell proliferation was
assessed with the MTS assay. Results are the means 6 SEM for at least 3 measurements from three individual experiments. Statistical analysis was
performed within each cell line. Bars that do not share a letter designation are significantly different within a treatment group (p,0.05). Black bars:
Ovcar3, Grey: CaOv3, Light grey: Skov3.
doi:10.1371/journal.pone.0016179.g003
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Figure 4. Effect of TZD treatment on Ovcar3 cell proliferation. Ovcar3 cells were serum starved for 24 hours and treated for an additional
24 hours with vehicle control (DMSO) or 0.1, 1.0 or 10 mM of CGZ (A), TGZ (B), Rosi (C), Pio (D). Cell proliferation was assessed with the BrdU assay.
Results are the means 6 SEM for at least 3 measurements from three individual experiments. Bars that do not share a letter designation are
significantly different within a treatment group (p,0.05).
doi:10.1371/journal.pone.0016179.g004

and TGZ on proliferation were not overcome by the presence of
the DN form of PPARc (Figure 10). Luciferase assays were run on
samples in the same plates in order to ensure that cells were being
transfected and expression of the DN caused the expected
decrease while overexpression of wild type PPARc increased
PPRE activity, respectively (data not shown). In concordance with
the BrdU assays, cell cycle data also indicate that the effect of CGZ
and TGZ are not PPARc dependent (data not shown).

different TZDs. For example, T007 was able to completely block
the effects of CGZ on cell proliferation but had no effect on the
TGZ mediated decrease in proliferation. In addition, the use of the
GW9662 or the T007 compounds alone did not affect proliferation on their own as was expected. This may be due to the fact
that these antagonists may be mixed agonists or not PPARc
specific [9,26]. These findings indicate that the use of a
pharmacological approach employing reported PPARc antagonists alone does not answer the question as to whether the effect of
the TZDs act through PPARc. This led us to use a molecular
approach using DN or OE PPARc constructs to investigate
whether the effects seen on cell proliferation and cell cycle were
PPARc dependent or independent.
Transfecting cells with DN or OE forms of PPARc without the
presence of ligands did not change cell proliferation as indicated
by BrdU assays (Figure 10). More importantly, the effects of CGZ
PLoS ONE | www.plosone.org
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TZDs have been shown to have a wide range of effects on cancer
cells. The presumed target of TZDs, PPARc, is overexpressed in a
variety of cancers including breast, lung, colon, prostate and ovary
[2,27,28,29]. Although, the exact role TZDs and PPARc play in
ovarian cancer remains unknown, this study demonstrates that
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Figure 5. Effect of TZDs on PPARc mRNA and protein expression. PPARc mRNA and protein expression were measured in Ovcar3 cells using
(A) Real time PCR and (B) western blot analysis after TZD treatment. Cells were serum starved for 24 hours and treated for an additional 24 hours
with vehicle control (DMSO) or one of the following: 10 mM of Rosi, CGZ, TGZ, or Pio. Results are the means 6 SEM for at least 3 measurements from
two individual experiments. Bars with different superscripts are significantly different (p,0.05).
doi:10.1371/journal.pone.0016179.g005

differences in cell culture conditions where, for example,
investigators have used 1% FBS [39], 5% FBS [35,36,37,38,39]
or 10% FBS [21]. The present findings demonstrate that this
decrease in proliferation is due to an increase in cell cycle arrest
rather than an increase in apoptosis. Similarly, other reports have
shown that TZDs lead to the degradation of cyclin D1 in prostate
cancer [40], which causes cell cycle arrest, and a decrease in tumor
cell proliferation. Likewise, in A2780 ovarian cancer cells, CGZ
decreases cyclin D1 along with other pro-survival factors resulting
in cell cycle arrest [21]. Yang and colleagues [20] reported that
CGZ and TGZ treatment of ES-2 and PA-1 ovarian cancer cells
resulted in cell cycle arrest; however, this change in cell cycle
kinetics was associated with increased levels of apoptosis. Although
our studies support the previous findings in different ovarian
cancer cells that the TZDs decrease cell proliferation by arresting
cells in the G0/G1 stage of the cell cycle, the possibility exists that
the higher concentrations of TZDs used in these previous studies
results in the induction of apoptosis [20].
The present study demonstrates that each of the TZDs has
distinct actions on ovarian cancer cell proliferation. CGZ and TGZ
cause a dramatic decrease in ovarian cancer cell proliferation whilst
Rosi and Pio had no effect. This is not unexpected as each TZD has
a different affinity and binding to PPAR [7,41], recruits different
coactivators [42] and may elicit distinct cellular responses. These
unique actions have led to the concept that the TZDs are selective

CGZ and TGZ have anti-proliferative actions on three ovarian
cancer cell lines, whilst Rosi and Pio have no effect. The fact that
these anti-proliferative actions are seen in all three cell lines suggests
that this is a common phenomenon and not confined to a single
ovarian cancer cell line. The experiments described herein also
demonstrate that the four TZDs have distinct actions on ovarian
cancer cells possibly through both PPARc dependent as well as
independent pathways. Although several reports indicate that
different cell lines respond differently to TZDs, [30,31,32,33], to
our knowledge, a direct comparison between these four TZDs in
ovarian cancer and delineating whether these effects are PPARc
dependent using molecular, physiological and pharmacological
approaches has not been investigated.
In the present study, 10 mM of CGZ and TGZ decreased cell
proliferation in all three of the ovarian cancer cell lines studied.
These observations are in concordance with other studies utilizing
ovarian cancer cells as well as other cell lines where CGZ and/or
TGZ decreased MTT activity [20,21,34]. However, our findings
are in contrast to cancer cell lines from other tissues such as breast,
thyroid, bladder and others that usually require much higher
concentrations of TZDs to elicit a biological response. In fact,
doses up to 100 mM, which exceed the reported ligand specific
concentrations of 10 mM or less [12], may be required before an
inhibition of proliferation is seen [35,36,37,38,39]. However, these
differences may be due in part to the use of different cells lines or
PLoS ONE | www.plosone.org
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Figure 6. Annexin V assay to detect apoptosis in Ovcar3 cells.
Ovcar3 cells were serum starved for 24 hours and treated with vehicle
control (DMSO) or 10 mM of CGZ or TGZ for (A) 4 hours, (B) 8 hours, or
(C) 12 hours. Results are the means 6 SEM of 3 measurements from
three individual experiments. Light gray bars represent viable cells; dark
gray bars represent cells undergoing early and late apoptosis as well as
those that are dead. Bars that do not share a letter or number
designation are significantly different (p,0.05).
doi:10.1371/journal.pone.0016179.g006

PLoS ONE | www.plosone.org

Figure 7. Cell cycle kinetics using flow cytometry. Ovcar3 cells
were serum starved for 24 hours and treated for an additional 24 hours
with vehicle control (DMSO) or 10 mM of CGZ or TGZ. (A) G0/G1, (B) G2,
(C) S phase. Results are the means 6 SEM for at least 3 measurements
from three individual experiments. Bars that do not share a letter or
number designation are significantly different (p,0.05).
doi:10.1371/journal.pone.0016179.g007
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Figure 8. PPRE Luciferase promoter activity assay. Ovcar3 cells were double transfected with a PPRE construct and one of the following: Empty
vector, DN, or OE PPARc. After the double transfections, cells were treated for 24 hours with vehicle control (DMSO) or 10 mM of (A) CGZ, (B) TGZ, (C)
Rosi, (D) or Pio. Results are the means 6 SEM for at least 3 measurements from three individual experiments. Bars that do not share a letter
designation are significantly different (p,0.05).
doi:10.1371/journal.pone.0016179.g008

contrast, the highest expression of PPARc protein was observed
when cells were treated with Rosi. This discordance between the
expression of PPARc mRNA and protein after TZD treatment has
not been observed nor examined previously, however, the levels of
PPARc protein after TZD treatment have been shown to be
highly variable between ES-2 and PA-1 ovarian cancer cells [21].
We postulated that examination of a static 24 hour time point
might not accurately capture the induction of PPARc mRNA and
protein. We therefore assessed the level of PPARc mRNA as well
as protein patterns at different times after TZD treatment and
observed a lack of correlation between PPARc mRNA and protein
expression at all time points. An alternative theory to explain this
discordance is that the increase in expression of PPARc mRNA
when cells are treated with TGZ may increase the turnover and
degradation of PPARc protein thereby reducing protein expression. This has been previously demonstrated in other systems
where it was shown that with increasing doses of TZDs, there was
an increase in PPARc protein degradation which resulted in a

modulators of PPARc and therefore target distinct genes resulting in
tissue selectivity [12,42,43,44]. In addition, TZDs have different
specificities for PPARs. For example, Rosi and Pio are considered
the most potent PPARc agonists out of the four TZDs used in this
study [11]. The findings that these potent PPARc agonists do not
inhibit cell proliferation further support our hypothesis that the
actions of the TZDs may be independent of PPAR. Furthermore,
Rosi, CGZ and TGZ are specific to PPARc while Pio has been
shown to also activate PPARa [45,46]. Hence, our data may reflect
the differences in the selective modulation of PPARc, differences in
the specificity for PPARc, or the activation of distinct PPARc
independent pathways.
To begin to understand the selective modulation of PPARc by
TZDs in ovarian cancer cells, we examined the mRNA and
protein expression profiles of PPARc and the activation of
PPARc’s promoter following TZD treatment. There is a dramatic
increase in PPARc mRNA expression when Ovcar3 cells were
treated with TGZ and to a lesser extent with CGZ and Rosi. In
PLoS ONE | www.plosone.org
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Figure 9. Effect of PPARc antagonists on Ovcar3 proliferation. Cells were treated with GW9662 (A) or T007 (B) for 24 h and cell proliferation
was assessed. Results are the means 6 SEM for at least 4 measurements. Bars that do not share a letter designation are significantly different
(p,0.05).
doi:10.1371/journal.pone.0016179.g009

points. Hence, we tested the effect of TZDs on promoter activity at
4, 8, 24 and 32 hours. There were modest increases in luciferase
activity in cells treated with CGZ at 8 and 32 hours (data not
shown), which were insufficient to account for the changes in
PPAR(expression. Discordance between protein levels and
PPAR(activity has been previously seen in breast cancer cells but
the exact mechanism underlying this difference remains unknown
[34]. However, such an observation suggests that analysis of only
PPARc protein levels may mistakenly be used to attribute cellular
effects or responsiveness to treatments.
The TZDs did not increase endogenous PPAR activity in these
cells, however, TZD treatment increased luciferase activity when
PPARc was overexpressed in Ovcar3 cells. This indicates that
these cells constitutively activate PPARc and, when the receptor is
highly abundant, further activation is possible. This activation is
not limited by RXR, since 9-cis-RA does not affect the PPRE
activity in Ovcar3 cells when transfected with empty, DN, or
wildtype PPARc vectors. The difference in endogenous ligands or
activating capacity between cells could lead to an increase in
endogenous transactivation and potentially, an increased receptor
degradation rate. Therefore, cellular levels of PPARc protein do
not reflect the total activity of PPARc or the capacity of exogenous
ligands to overcome endogenous PPARc activation.
The present study explored whether proliferation and cell cycle
arrest observed after TZD treatment were due directly to PPARc.
Previously, the PPARc antagonists T007 and GW9662 were used
to determine whether the effects of TZDs are PPARc dependent
[20,49]. Our results showed no changed in cell proliferation when
cells were treated with these two antagonists alone. When cells
were treated with the antagonists in combination with TZDs, there
were differential changes in cell proliferation. However, there are
controversies regarding the specificity of PPARc antagonists
[9,26], in particular that they can activate, rather than inactivate
the PPRE reporter in normal breast cell lines [9]. Antagonists may
also have PPARc independent effects [26]. Due to these potential
confounding non-PPARc actions of the PPARc antagonists, we
used an alternative molecular approach to determine whether
TZDs act through PPARc. To accomplish this, we transfected
Ovcar3 cells with a dominant negative form of PPARc or a wild
type overexpression PPARc construct. The DN form of PPARc
provided a more robust decrease in PPRE when compared to
shRNA (data not shown). The observation that the DN decreased
PPRE promoter activity again illustrates that there is endogenous
transactivation of PPARc taking place in these cells. In addition,
the finding that the TZDs cause an increase in reporter activity
when the level of PPARc is overexpressed demonstrates that
TZDs convey part of their activity through PPARc when there are
sufficient, unoccupied receptors available. One can argue that the
effect on proliferation may be due to the TZDs competing for the
receptor with the endogenous ligand and recruiting different coactivators [42]; however, all four TZDs showed a similar trend in
terms of luciferase activity indicating the possibility that they may
convey some actions through PPARc but the effects on
proliferation may not be PPARc dependent. This was evident
when Ovcar3 cells were concurrently transfected with the wild
type or DN PPARc, treated with CGZ or TGZ, and cell
proliferation still decreased, indicating that the effects of CGZ and
TGZ are not PPARc dependent. However the possibility exists
that, even in the presence of the DN, there is still sufficient PPARc

decrease in the steady state levels of the protein in endothelial cells
[24,25]. This is hypothesized to occur because TZDs mediate
changes in the phosphorylation state of PPARc by MEK which
leaves PPARc susceptible to degradation [47]. In light of this
information, our protein data could be explained by the fact that
TZDs cause differential degradation of PPAR(after activation and
that the turn-over rate of PPAR(protein in cells treated with TGZ
is faster than that of CGZ and Rosi resulting in a decrease in
protein levels. In addition, it is possible that Rosi increases the
protein stability of PPAR(whilst the effects on proliferation after
treatment with CGZ and TGZ are PPAR(independent. Alternatively, TZDs may cause changes in the protein itself, such as
phosphorylation, which alters other actions of the protein rather
than just changing its overall transactivation as recently been
shown by Choi et al. [48].
In light of our results that showed a lack of correlation between
the levels of PPAR(mRNA and protein after TZD treatment, we
explored the changes in activation of a PPAR(reporter as an index
of PPAR(activity after TZD exposure. Surprisingly, PPAR(activity
was not stimulated by any of the 4 TZDs after 24 h of treatment,
in contrast to previous reports in other ovarian cancer cell lines
that 50 mM of CGZ increased luciferase activity of a PPRE
reporter by 18 h [21]. Based on this previous report, we speculated
that promoter activation might be occurring at earlier or later time

Figure 10. Effect of CGZ and TGZ treatment on Ovcar3 cell
proliferation in cells transfected with DN or OE PPARc
constructs. Ovcar3 cells were double transfected, serum starved for
24 hours and treated for an additional 24 hours with vehicle control
(DMSO) or10 mM of CGZ or TGZ. Cell proliferation was assessed with a
BrdU assay. Results are the means 6 SEM for at least 9 measurements
from three individual experiments. Bars that do not share a letter
designation are significantly different within a treatment group
(p,0.05).
doi:10.1371/journal.pone.0016179.g010
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man Chemicals (Ann Arbor, MI), while 9-cis-retinoic acid (9-CisRA) was a purchased from MP Biomedicals (Solon, OH).

to impact cell proliferation. Irrespective, this approach provided
evidence that there was a lack of an effect of endogenous PPARc
on cell proliferation since the expression of a DN or OE form of
PPARc did not affect cell proliferation.
In summary, our findings demonstrate that CGZ and TGZ
decrease cell proliferation mainly through cell cycle arrest. The
current study establishes that these effects appear to be TZD specific
as these changes are not seen in cells treated with Rosi or Pio, unlike
previous reports [20,21], yet all four TZDs drive the same levels of
PPRE activity. This could be due to several hypothetical
explanations. Rosi and Pio may be recruiting different coactivators
than those of CGZ and TGZ. Alternatively, the effects of TZDs on
proliferation may be via changes in the Akt/PTEN/mTOR
pathway [50]. Rosi has been previously shown to suppress the
AKT pathway via increasing the expression of PTEN in cells such as
MCF7 [51] and NSCLC [27]. Thus, it is possible that CGZ and
TGZ cause a more pronounced effect on the AKT/mTOR
pathway than Rosi and Pio. Another plausible explanation is that
variations in the specificity of these ligands for PPARc, thus, causing
changes in promoter activity such as a prolonged DNA binding
activity rather than an increase in magnitude. Alternatively, the
changes in cell proliferation with CGZ and TGZ may be
independent of PPARc. For example, adding DN in combination
to CGZ or TGZ did not rescue Ovcar3 cells from the decrease in
proliferation, indicating that these compounds are at least partially
acting in a PPARc independent manner.
Our findings also demonstrate that PPARc agonists stimulate
PPARc expression, but to varying degrees in different ovarian cancer
cells. This stimulation of PPARc mRNA is not mirrored by PPARc
protein levels and interestingly, the levels of PPARc protein do not
accurately predict PPRE reporter activity. These data suggest that
TZD actions may be beneficial in hindering the proliferative
capacity of tumor cells albeit potentially in a PPARc independent
manner. This observation is the first report to our knowledge that
utilized both molecular and pharmacological approaches to
demonstrate that TZDs convey their actions on ovarian cancer cells
independent of PPARc. Since TZDs have often been suggested as
plausible therapeutic agents due to their effects on proliferation and
antitumor potential in ovarian cancer [52], it will be crucial to
further investigate potential targets of TZDs in order to understand
their mechanism of action and uncover novel therapeutic targets.

Cell Line propagation
Cells were grown at 37uC in a 5% CO2 environment until cells
reached the desired confluence described below. Cells were then
serum starved for 24 hours and treated for an additional 24 hours
with vehicle control (DMSO), or 0.1–10 mM of one of the
following: Rosi, CGZ, TGZ, or Pio. The maximum concentration
of TZDs used was 10 mM as PPARc specific actions are reported
with TZDs at concentrations #10 mM [20]. All experiments were
performed as outlined above unless otherwise noted. All
experiments were done at least 3 times, with 3 replicates each.

RNA Isolation
In order to examine cellular PPARc expression, cells were
grown to 60–90% confluence and treated as described above for
24 hours. Total RNA was isolated using the RNeasy RNA
isolation kit from Qiagen (Valencia, CA) according to the
manufacturer’s protocol. RNA samples were stored at 280uC
until used for real time PCR.

Real time PCR
The reverse transcription reaction was accomplished using the
TaqManH one step rtPCR Master Mix kit from Applied Biosystems
(Foster City, CA). Quantitative PCR was performed using a
Stratagene Mx3000P real-time thermal cycler and the TaqMan
methodology. Pre-optimized primers for PPARc and 18S mRNA
probes with a 59 fluorescent reporter (FAM) were purchased from
Applied Biosystems. Each RT reaction was performed using 200 ng
of RNA at 48uC for 30 minutes. The RT reaction product was then
subjected to real time PCR by incubating the reaction at 95uC for
10 min followed by 40 cycles of denaturing (95uC for 15 s) and reannealing (60uC for 1 min). The amount of mRNA present was
recorded as a cycle number (Ct) where the message reaches a fixed
threshold. Ct was normalized to ribosomal RNA 18S which was
then compared to control by the equation 22DDCt.

Western blot analysis
Western blot analysis was performed in order to examine the
expression of PPARc protein in the different cell lines as well as to
evaluate the effect of experimental treatment on protein
expression. To accomplish this, cells were grown to 60–90%
confluence, treated as previously described and lysed using a lysis
buffer containing a protease inhibitor cocktail (Roche, Mannheim,
Germany). Protein concentrations were quantified using the
Bradford assay (BioRad, Hercules, CA). A total of 50 mg of
protein was run on a 10% SDS gel, which was then transferred to
a nitrocellulose membrane (BioRad). Membranes were incubated
with antibodies against PPARc NR1C3 (1:250, R&D systems,
Minneapolis, MN) (Figure 1B) or PPARc E-8 (1:150, Santa Cruz
Biotechnology Santa Cruz, CA) (Figure 6B), overnight at 4uC in
5% milk (TBST) or actin a (1:1000, Sigma-Aldrich, A 5060) for
1 hour. Membranes were washed and incubated with secondary
anti-mouse or anti rabbit horseradish peroxidase (HRP)-conjugated antibody respectively (Santa Cruz). PPARc and actin a were
visualized using an enhanced chemiluminescence detection system
(Pierce, Rockford, IL) and exposure to x-ray film.

Materials and Methods
Ethics Statement
This study does not involve human participants or animal work.
As such, an ethics statement is not required.

Cells, Media and Reagents
All cell lines (Ovcar3, CaOv3, Skov3 and MCF7) were obtained
from the American Type Culture Collection ATCC (Rockville,
MD). Ovcar3, CaOv3 and Skov3 cell culture media were obtained
from the American Type Culture Collection ATCC (Rockville,
MD). Ovcar3 cells were grown in Rossman-Park-MemorialInstitute (RPMI) 1640 media supplemented with 20% fetal bovine
serum (FBS) containing penicillin/streptomycin/amphotericin B
(Gibco-Invitrogen, Carlsbad, CA). CaOV3 and Skov3 cells were
grown in Dulbecco’s Modified Medium (DMEM) and McCoy’s
5A medium respectively. MCF7 media (DMEM-31053) was
purchased from Invitrogen. DMEM, McCoy’s and MCF7 media
were supplemented with 10% FBS and antibiotics as above.
Ciglitazone (CGZ), Rosiglitazone (Rosi), Troglitazone (TGZ),
Pioglitazone (Pio) GW9662 and T007 (T0070907 (N-(49-aminopyridyl-2-chloro-5-nitrobenzamide)) were purchased from CayPLoS ONE | www.plosone.org

Proliferation assays: MTS and BrdU assays
The effect of TZDs on cell proliferation was assessed with the
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2(4-sulfophenyl)-2H-tetrazolium) assay (Promega, Madison, WI),
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according to the manufacturer’s protocol.). Briefly, after TZD
treatment, cells were treated with 100 mL of MTS/PMS solution
from Promega’s CellTiter 96 Aqueous one solution cell proliferation assay for 4 hours. Proliferation was measured by colorimetric
absorbance at 492 nm. The incorporation of BrdU into DNA was
assessed using a Cell proliferation, ELISA BrdU kit (Roche). In
brief, cells were labeled after culture with BrdU labeling solution
overnight. Afterwards, cells were fixed, the DNA denatured, and
peroxidase the BrdU complex was then detected and quantitated
colorimetrically at 450 nm. Treatments were normalized to
control (DMSO vehicle treatment) and expressed as the relative
fold change compared to the control. BrdU proliferation was also
preformed on cells that were transfected with or without a
dominant negative (DN) or overexpressing (OE) PPARc vector.
Cells were double transfected as described under the constructs
and transfection section below, then serum starved for 24 hours
and treated for 24 hours prior to running a BrdU assay in
combination with either the agonists or antagonists.

determine whether TZD treatments result in the activation of the
PPARc promoter, PPRE reporter constructs were utilized. This
construct, 3XPPRE-TK-pGL3, contains three copies of the PPRE
sequence (AGGACAAAGGTCA). The DN construct was a kind
gift from Drs. O’Rahilly and Chatterjee (Cambridge University,
U.K.) and has been modified to introduce a stop codon at amino
acid 462 and has been previously characterized and used by our lab
[19]. The wild type overexpression (OE) PPARc construct was
made by our laboratory. The luciferase construct lacking the PPRE
and the Renilla constructs were purchased from Promega.
Approximately 120,000 cells (about 30% confluence) were plated
per well for all transfection experiments. To compare the PPRE
activity across the three different cell lines, cells were either
transfected with a 3XPPRE mTK-Luc or with two vectors (a
luciferase lacking PPRE and a Renilla containing vector) [55]. Cells
were transfected two subsequent days and then lysed on day 3 for
analysis. To inspect the effect of TZD treatment on PPRE activity,
cells were transiently double transfected with a total of 0.4 mg DNA
per well. Each well was transfected with 0.2 mg of pGL3 plasmid
containing 3XPPRE mTK-Luc and Renilla [55] using FuGENE
transfection reagent (Roche). Cells were also transfected with 0.2 mg
of one of the following: Empty vector control construct, DN, or wild
type overexpression (OE) PPARc. Cell transfection was repeated for
an additional 24 hours. Afterwards, cells were treated with 10 mM
of one of the following: Vehicle control (DMSO), Rosi, CGZ, TGZ,
Pio or 9-cis-RA for an additional 24 hours. Cells were lysed with
150 ml of passive lysis buffer and treated according to the
manufacturer’s instructions (Promega dual luciferase assay kit,
Promega). A total of 20 ml was used for luminometry. Luminometry
was performed on a Berthold Technologies Lumat 9507 (Willbad,
Germany). Ratios between luciferase and Renilla were used to
calculate promoter activity and adjust for differences in transfection
efficiency. Transfection efficiencies were calculated and revealed
that the highest transfection efficiency was achieved in Skov3 cells
followed by Ovcar3 with the CaOv3 cells having the lowest
transfection efficiency. Data is presented as a relative expression
normalized to the vehicle control.

Cell Cycle assay
Flow cytometry was used to determine the effect of TZD
treatment on cell cycle kinetics, as previously described by Vindelov
[53]. Cells were cultured until they were 60–90% confluent and
treated as described above. Briefly, cells were washed with PBS,
trypsinized for 5–10 minutes and then treated with trypsin inhibitor
and ribonuclease A for 30 minutes. Subsequently, propidium iodide
(final concentration 50 ug/mL) in combination with sperimine HCl
was added to the cells for 30 minutes in the dark at 4uC. The
suspension was analyzed using a FacsCalibur flow cytometer from
Becton Dickson (San Jose, CA) at the core facility at the University
of Kentucky using Mod FitLT V.3.1 software. Ratios of cells in the
G0/G1, S, and G2/M phases of cell cycle were determined on the
basis of their DNA content and presented as cell percentage at the
end stage of the cell cycle. Cell cycle histograms were obtained from
3 determinations, each with a total of 100,000 cells/treatment. Cell
cycle was also performed on cells that were double transfected with
either DN or OE PPARc. Cells were double transfected as outlined
under the constructs and transfection section below, then serum
starved for 24 hours and treated for 24 hours. Consequently, a cell
cycle assay was performed.

Statistical analysis
All data are presented as means 6 SEM. One-way analysis of
variance (ANOVA) or Welch’s t-test was used to test differences
among treatments. If the ANOVA showed significant effects, post
hoc tests were performed using Tukey’s or Bonferroni, in order to
identify significant differences among treatments. The means were
compared with p#0.05 considered significant. Statistical analysis
was performed using a statistical analysis software [56].

Apoptosis assay
Cells were grown as described above and treated for 4, 8 or
12 hours with one of the following: Vehicle control (0.1% DMSO),
or 10 mM of CGZ or TGZ. Cells were then analyzed for apoptosis
using the Vybrant Apoptosis Assay kit per the manufacturer’s
protocol (Invitrogen). Briefly, cells were washed twice with PBS,
trypsinized and centrifuged. Annexin V Binding buffer was used to
resuspend the pellet and Alexa Flour 488 annexin V and propidium
iodide solution was added to the cells and incubated at room
temperature for 15 minutes. Samples were analyzed using flow
cytometry readings at 530 nm and .575 nm in the FacsCalibur
flow cytometer at the core facility at the University of Kentucky.
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Constructs and transfection assays
PPARc regulates gene expression by binding to a specific
Peroxisome Proliferator Response Element (PPRE) [54]. To
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